A Phase 1 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Cotadutide in Chinese Overweight/Obese Subjects With Type 2 Diabetes Mellitus
Latest Information Update: 09 Nov 2023
At a glance
- Drugs Cotadutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Acronyms COTA China PK
- Sponsors AstraZeneca
Most Recent Events
- 20 Jan 2023 Status changed from active, no longer recruiting to completed.
- 18 Oct 2022 Planned End Date changed from 30 Dec 2022 to 13 Dec 2022.
- 18 Oct 2022 Planned primary completion date changed from 30 Dec 2022 to 13 Dec 2022.